Loading
A phase 2 trial of Raludotatug deruxtecan and Ifinatamab deruxtecan in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) is a phase 2 interventional study registered as NCT06780085 by Merck Sharp & Dohme LLC, with 96 participants planned, started 2025-05-13 and due to reach its primary completion in 2032-03-12. Interventions recorded: Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel, 5-hydroxytryptamine subtype 3 receptor antagonist, Neurokinin-1 receptor antagonist and Corticosteroid.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Raludotatug deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Raludotatug deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/